{"id":78017,"date":"2026-05-08T15:34:13","date_gmt":"2026-05-08T15:34:13","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/78017\/"},"modified":"2026-05-08T15:34:13","modified_gmt":"2026-05-08T15:34:13","slug":"q1-fy2026-earnings-preview-after-fda-move-and-nvo-collaboration","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/78017\/","title":{"rendered":"Q1 FY2026 Earnings Preview After FDA Move and NVO Collaboration"},"content":{"rendered":"

Healthcare stocks<\/a> have struggled in 2026. With a year-to-date (YTD) loss of about 6%, that corner of the market has been the worst performer among all 11 sectors of the S&P 500 in 2026.<\/p>\n

Hims & Hers Health Today\"HimsHIMS<\/a>\"HIMS<\/a><\/p>\n

Hims & Hers Health<\/p>\n

$26.41 +0.76\u00a0(+2.97%) As of 11:33 AM Eastern This is a fair market value price provided by Massive. Learn more.<\/a>52-Week Range$13.74<\/p>\n

\u25bc<\/p>\n

$70.43<\/p>\n

P\/E Ratio51.88<\/p>\n

Price Target$31.86<\/p>\n

While that has been reflected in the YTD losses of some of Big Pharma\u2019s biggest names<\/a>, it has also adversely affected mid-cap stocks like telehealth platform Hims & Hers Health NYSE: HIMS<\/a>, which has fallen by more than 23% in 2026.<\/p>\n

One day after a big announcement<\/a> from the U.S. Food & Drug Administration (FDA) caused shares of HIMS to jump by nearly 4%, the stock gave it all back on Thursday, falling by nearly 5% as traders locked in profits.<\/p>\n

Get Hims & Hers Health alerts:<\/p>\n

Sign Up<\/p>\n

But that wasn\u2019t enough to derail the stock\u2019s recent rally, which has seen HIMS gain nearly 32% over the past month and around 77% since its 52-week low on Feb. 27. As the company prepares to report Q1 2026 earnings<\/a> on May 11, here\u2019s what investors should watch for.<\/p>\n

Is the Novo Nordisk Partnership Already Paying Off?Novo Nordisk A\/S Today\"NovoNVO<\/a>\"NVO<\/a><\/p>\n

Novo Nordisk A\/S<\/p>\n

$45.68 -0.13\u00a0(-0.27%) As of 11:33 AM Eastern This is a fair market value price provided by Massive. Learn more.<\/a>52-Week Range$35.12<\/p>\n

\u25bc<\/p>\n

$81.44<\/p>\n

Dividend Yield3.83%<\/p>\n

P\/E Ratio10.72<\/p>\n

Price Target$65.56<\/p>\n

Following a well-publicized legal dispute<\/a> earlier this year with Denmark-based Novo Nordisk NYSE: NVO<\/a>\u2014the eighth largest publicly traded pharmaceutical company in the world with a market cap of more than $204 billion\u2014it\u2019s been smooth sailing for Hims & Hers.<\/p>\n

Since Novo Nordisk dropped its patent infringement lawsuit<\/a> on March 9, HIMS has been on a tear. Not only did the Danish firm abandon its case, but it also reached a deal that allows Hims & Hers to sell Novo Nordisk\u2019s brand-name Wegovy and Ozempic through its direct-to-consumer and virtual medical services platform.<\/p>\n

As part of that deal, Hims & Hers agreed to stop advertising its compounded GLP-1 products<\/a>, which given the FDA\u2019s announcement that it is proposing that semaglutide, tirzepatide, and liraglutide be excluded from its 503B bulks list<\/a>, could prove prescient for the company.<\/p>\n

Wall Street will be looking for how that deal has impacted Hims & Hers\u2019 top line. Despite the strategic shift being announced on March 9<\/a>, Novo Nordisk\u2019s GLP-1 products were not available for sale through the online platform until March 26. The books for Q1 closed on March 31, so those gross sales may not materialize on Hims & Hers\u2019 income statement until Q2.<\/p>\n

Will Hims & Hers Continue to Show Subscriber Growth?<\/p>\n

The market will also be looking for confirmation that Hims & Hers\u2019 total subscribers are holding above 2.5 million, if not steadily growing from there. That benchmark was reached near the end of 2025 and marked a more than 16% increase from the 2.2 million subscribers the company had at the end of 2024.<\/p>\n

That growth is proving to be sustainable, after Hims & Hers ended 2023 with 1.5 million. But more important than the raw subscriber count is how the telehealth company generates 90% of its recurring revenue from its customer base.<\/p>\n

Approximately 82% of its users remain on the platform for more than three months, and if Hims & Hers can demonstrate that it is sustainable, it should bolster full-year guidance.<\/p>\n

Meanwhile, analysts are expecting earnings per share (EPS) of around three to four cents<\/a>, which would mark an estimated 90% year-over-year decline. That may already be priced in, given the stock\u2019s YTD performance, but a miss could accelerate selling.<\/p>\n

The same goes for quarterly revenue, which consensus forecasts put in the range of $616 million to $619 million. Wall Street is already bracing for a \u201creset quarter\u201d after revenue growth<\/a> tapered from nearly 111% in Q1 2025 to less than 29% in Q4, so any surprise to the upside could spur another leg to the current rally.<\/p>\n

Analysts Are Taking a Wait-and-See ApproachHims & Hers Health Stock Forecast Today12-Month Stock Price Forecast:
$31.86
24.40% UpsideHold
Based on 17 Analyst RatingsCurrent Price$25.61High Forecast$68.00Average Forecast$31.86Low Forecast$18.00Hims & Hers Health Stock Forecast Details<\/a><\/p>\n

Despite an average 12-month price target of nearly $32, which implies potential upside of around 24%, Wall Street remains tepid on the stock.<\/p>\n

Of the 17 analysts currently covering HIMS, four assign it a Buy rating, 12 assign it a Hold rating, and just one assigns it a Sell rating. Overall, the stock receives a consensus Hold rating<\/a>.<\/p>\n

Institutional ownership<\/a> of nearly 64% falls within the typical range for mid-cap companies. Outflows of $1.62 billion have nearly caught up to inflows of $1.8 billion over the past 12 months after selling accelerated in Q4 2025. But that trend reversed in Q1, with institutional selling 88% lower than institutional buying.<\/p>\n

With a high beta of 2.43, the inherently volatile stock is currently being heavily targeted by bears. Concerningly, more than 35% of the float\u2014or nearly 70 million shares of the almost 228 million shares outstanding\u2014is currently shorted<\/a>.<\/p>\n

Still, strong earnings could shift sentiment and propel the stock closer to the consensus analyst price target. Shareholders and prospective investors should mark their calendars for Monday, May 11, when Hims & Hers Health reports Q1 2026 results<\/a>.<\/p>\n

Before you consider Hims & Hers Health, you’ll want to hear this.<\/p>\n

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks<\/a> that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Hims & Hers Health wasn’t on the list.<\/p>\n

While Hims & Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.<\/p>\n

View The Five Stocks Here <\/a><\/p>\n

\"Elon<\/p>\n

Explore Elon Musk\u2019s boldest ventures yet\u2014from AI and autonomy to space colonization\u2014and find out how investors can ride the next wave of innovation.<\/p>\n

Get This Free Report<\/a><\/p>\n

Like this article? Share it with a colleague.<\/p>\n

<\/a><\/a><\/a><\/a><\/a><\/a><\/a><\/p>\n

Link copied to clipboard.<\/p>\n